<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=896170837107954&amp;ev=PageView&amp;noscript=1">

Back to Press Releases

NeoTract, Inc. Announces Successful Live Case Transmission at AUA 2015

  

PLEASANTON, Calif. and NEW ORLEANS, La. –  NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced a successful live case using the UroLift® System to treat a patient with Benign Prostatic Hyperplasia (BPH) during the American Urological Association's 2015 Annual Meeting in New Orleans, La., to an audience of more than 1,500 attendees.

“The UroLift System provides an important option for men with BPH,” Daniel B. Rukstalis, M.D., urologist of Wake Forest Baptist Health, who performed the live case. “As demonstrated during the case, the procedure involves no cutting, heating, or removal of prostate tissue. Even better, patients experience immediate results, with rapid symptom relief, recover from the procedure quickly, and return to their normal routines with minimal downtime. I am thrilled with the results of patients I have treated with the UroLift system.”

The live case was moderated by Eugene Rhee, M.D., chief of Urologic Surgery at San Diego Medical Center, Kaiser Permanente.

Yesterday NeoTract also reported results of two studies of the UroLift System presented at the conference. Clinical data from the BPH6 Study showed that the UroLift device compares very well to surgical transurethral resection of the prostate (TURP), the most common BPH procedure, with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery. In addition, three-year data from the randomized L.I.F.T. IDE Study shows UroLift offers not only rapid improvement, but also durable relief for patients with BPH. After three years, patients treated with the UroLift device continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for symptom relief.

About Benign Prostatic Hyperplasia (BPH)
BPH, also known as enlarged prostate, is a medical condition in which the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. The condition is common, affecting approximately 37 million men in the United States alone. BPH symptoms
include sleepless nights and urinary problems, and can cause loss of productivity, depression and decreased quality of life. About one in four men experience BPH-related symptoms by age 55 and by age 70, over 80 percent of men suffer from BPH.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts or ablates prostate tissue to open the blocked urethra. While current surgical options, such TURP can be very effective in relieving symptoms, it can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).

About the UroLift System
The FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia and Canada. Learn more at www.UroLift.com.

About NeoTract
NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. The company’s initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.

###

Media Contact:
Nicole Osmer
650.454.0504
nicole@nicoleosmer.com

View PDF